Cisplatin-encapsulated TRAIL-engineered exosomes from human chorion-derived MSCs for targeted cervical cancer therapy.

IF 7.1 2区 医学 Q1 CELL & TISSUE ENGINEERING
Miaomiao Ye, Tingxian Liu, Liqing Miao, Huihui Ji, Zhihui Xu, Huihui Wang, Jian'an Zhang, Xueqiong Zhu
{"title":"Cisplatin-encapsulated TRAIL-engineered exosomes from human chorion-derived MSCs for targeted cervical cancer therapy.","authors":"Miaomiao Ye, Tingxian Liu, Liqing Miao, Huihui Ji, Zhihui Xu, Huihui Wang, Jian'an Zhang, Xueqiong Zhu","doi":"10.1186/s13287-024-04006-6","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Cisplatin (DDP) is an efficacious and widely applied chemotherapeutic drug for cervical cancer patients who are diagnosed as metastatic and inoperable, or desiring fertility preservation. Tumor necrosis factor (TNF)-related apoptosis inducing ligand (TRAIL) selectively triggers cancer cells apoptosis by binding to cognate death receptors (DR4 and DR5). Mesenchymal stem cells-derived exosomes (MSCs-Exo) have been regarded as ideal drug carriers on account of their nanoscale, low toxicity, low immunogenicity, high stability, biodegradability, and abundant sources.</p><p><strong>Methods: </strong>Human chorion-derived mesenchymal stem cells (hCD-MSCs) were isolated by adherent culture method. TRAIL-engineered hCD-MSCs (hCD-MSCs<sup>TRAIL</sup>) were constructed by lentivirus transfection, and its secreted Exo (hCD-MSCs-Exo<sup>TRAIL</sup>) were acquired by differential centrifugation and confirmed to overexpress TRAIL by western blotting. Next, nanoscale drug delivery systems (DDP & hCD-MSCs-Exo<sup>TRAIL</sup>) were fabricated by loading DDP into hCD-MSCs-Exo<sup>TRAIL</sup> via electroporation. The CCK-8 assay and flow cytometry were conducted to explore the proliferation and apoptosis of cervical cancer cells (SiHa and HeLa), respectively. Cervical cancer-bearing nude mice were constructed to examine the antitumor activity and biosafety of DDP & hCD-MSCs-Exo<sup>TRAIL</sup> in vivo.</p><p><strong>Results: </strong>Compared with hCD-MSCs-Exo, hCD-MSCs-Exo<sup>TRAIL</sup> weakened proliferation and enhanced apoptosis of cervical cancer cells. DDP & hCD-MSCs-Exo<sup>TRAIL</sup> were proved to retard cervical cancer cell proliferation and propel cell apoptosis more effectively than DDP or hCD-MSCs-Exo<sup>TRAIL</sup> alone in vitro. In cervical cancer-bearing mice, DDP & hCD-MSCs-Exo<sup>TRAIL</sup> evidently hampered tumor growth, and its role in inducing apoptosis was mechanistically associated with JNK/p-c-Jun activation and survivin suppression. Moreover, DDP & hCD-MSCs-Exo<sup>TRAIL</sup> showed favorable biosafety in vivo.</p><p><strong>Conclusions: </strong>DDP & hCD-MSCs-Exo<sup>TRAIL</sup> nanoparticles exhibited great promise for cervical cancer treatment as an Exo-based chemo-gene combinational therapy in clinical practice.</p>","PeriodicalId":21876,"journal":{"name":"Stem Cell Research & Therapy","volume":"15 1","pages":"396"},"PeriodicalIF":7.1000,"publicationDate":"2024-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11536590/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Stem Cell Research & Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s13287-024-04006-6","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CELL & TISSUE ENGINEERING","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Cisplatin (DDP) is an efficacious and widely applied chemotherapeutic drug for cervical cancer patients who are diagnosed as metastatic and inoperable, or desiring fertility preservation. Tumor necrosis factor (TNF)-related apoptosis inducing ligand (TRAIL) selectively triggers cancer cells apoptosis by binding to cognate death receptors (DR4 and DR5). Mesenchymal stem cells-derived exosomes (MSCs-Exo) have been regarded as ideal drug carriers on account of their nanoscale, low toxicity, low immunogenicity, high stability, biodegradability, and abundant sources.

Methods: Human chorion-derived mesenchymal stem cells (hCD-MSCs) were isolated by adherent culture method. TRAIL-engineered hCD-MSCs (hCD-MSCsTRAIL) were constructed by lentivirus transfection, and its secreted Exo (hCD-MSCs-ExoTRAIL) were acquired by differential centrifugation and confirmed to overexpress TRAIL by western blotting. Next, nanoscale drug delivery systems (DDP & hCD-MSCs-ExoTRAIL) were fabricated by loading DDP into hCD-MSCs-ExoTRAIL via electroporation. The CCK-8 assay and flow cytometry were conducted to explore the proliferation and apoptosis of cervical cancer cells (SiHa and HeLa), respectively. Cervical cancer-bearing nude mice were constructed to examine the antitumor activity and biosafety of DDP & hCD-MSCs-ExoTRAIL in vivo.

Results: Compared with hCD-MSCs-Exo, hCD-MSCs-ExoTRAIL weakened proliferation and enhanced apoptosis of cervical cancer cells. DDP & hCD-MSCs-ExoTRAIL were proved to retard cervical cancer cell proliferation and propel cell apoptosis more effectively than DDP or hCD-MSCs-ExoTRAIL alone in vitro. In cervical cancer-bearing mice, DDP & hCD-MSCs-ExoTRAIL evidently hampered tumor growth, and its role in inducing apoptosis was mechanistically associated with JNK/p-c-Jun activation and survivin suppression. Moreover, DDP & hCD-MSCs-ExoTRAIL showed favorable biosafety in vivo.

Conclusions: DDP & hCD-MSCs-ExoTRAIL nanoparticles exhibited great promise for cervical cancer treatment as an Exo-based chemo-gene combinational therapy in clinical practice.

从人绒毛膜间充质干细胞中提取顺铂包裹的 TRAIL 工程外泌体,用于宫颈癌靶向治疗。
背景:顺铂(DDP)是一种有效且广泛应用的化疗药物,适用于确诊为转移性、无法手术或希望保留生育能力的宫颈癌患者。肿瘤坏死因子(TNF)相关凋亡诱导配体(TRAIL)通过与同源死亡受体(DR4和DR5)结合,选择性地触发癌细胞凋亡。间充质干细胞衍生的外泌体(MSCs-Exo)因其纳米级、低毒性、低免疫原性、高稳定性、生物可降解性和丰富的来源而被视为理想的药物载体。通过慢病毒转染构建了TRAIL工程化hCD-MSCs(hCD-MSCsTRAIL),并通过差速离心获得了其分泌的Exo(hCD-MSCs-ExoTRAIL),经Western印迹证实其过表达TRAIL。接着,通过电穿孔将 DDP 装入 hCD-MSCs-ExoTRAIL 中,制成了纳米级给药系统(DDP 和 hCD-MSCs-ExoTRAIL)。CCK-8试验和流式细胞术分别检测了宫颈癌细胞(SiHa和HeLa)的增殖和凋亡情况。通过构建宫颈癌裸鼠来检验 DDP 和 hCD-MSCs-ExoTRAIL 在体内的抗肿瘤活性和生物安全性:结果:与hCD-MSCs-Exo相比,hCD-MSCs-ExoTRAIL能减弱宫颈癌细胞的增殖并增强其凋亡。在体外实验中,DDP 和 hCD-MSCs-ExoTRAIL 比单独使用 DDP 或 hCD-MSCs-ExoTRAIL 能更有效地延缓宫颈癌细胞增殖和促进细胞凋亡。在患宫颈癌的小鼠中,DDP 和 hCD-MSCs-ExoTRAIL 能明显抑制肿瘤生长,其诱导细胞凋亡的作用与 JNK/p-c-Jun 激活和存活素抑制机理有关。此外,DDP和hCD-间充质干细胞-ExoTRAIL在体内表现出良好的生物安全性:结论:DDP & hCD-间充质干细胞-ExoTRAIL纳米颗粒作为一种基于Exo的化疗基因组合疗法,在宫颈癌的临床治疗中大有可为。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Stem Cell Research & Therapy
Stem Cell Research & Therapy CELL BIOLOGY-MEDICINE, RESEARCH & EXPERIMENTAL
CiteScore
13.20
自引率
8.00%
发文量
525
审稿时长
1 months
期刊介绍: Stem Cell Research & Therapy serves as a leading platform for translational research in stem cell therapies. This international, peer-reviewed journal publishes high-quality open-access research articles, with a focus on basic, translational, and clinical research in stem cell therapeutics and regenerative therapies. Coverage includes animal models and clinical trials. Additionally, the journal offers reviews, viewpoints, commentaries, and reports.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信